

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ROCHE HOLDING LTD</u> <hr/> (Last) (First) (Middle) <u>GRENZACHERSTRASSE 124, 4070</u> <hr/> (Street) <u>BASEL V8 CH-4070</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>10/25/2023</u>	3. Issuer Name and Ticker or Trading Symbol <u>Aligos Therapeutics, Inc. [ALGS]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value \$0.0001 per share	11,025,941	I	See Footnote ⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Warrant (Right to Buy)	10/25/2023	10/25/2030	Common Stock	3,966,800	0.7568	I	See Footnote ⁽¹⁾

1. Name and Address of Reporting Person* <u>ROCHE HOLDING LTD</u> <hr/> (Last) (First) (Middle) <u>GRENZACHERSTRASSE 124, 4070</u> <hr/> (Street) <u>BASEL V8 CH-4070</u> <hr/> (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>ROCHE FINANCE LTD</u> <hr/> (Last) (First) (Middle) <u>GRENZACHERSTRASSE 124, 4070</u> <hr/> (Street) <u>BASEL V8 CH-4070</u> <hr/> (City) (State) (Zip)

Explanation of Responses:

1. Represents shares held by Roche Finance Ltd. ("Roche Finance"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd. ("Roche Holding"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 3 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 3.

By: /s/ Peter Trybus,
Authorized Signatory.

ROCHE FINANCE LTD.,

By: /s/ Carole 11/07/2023
Nuechterlein, Authorized
Signatory.

ROCHE HOLDING LTD.,

By: /s/ Peter Trybus, 11/07/2023
Authorized Signatory.

ROCHE HOLDING LTD.,

By: /s/ Claudia 11/07/2023
Boeckstiegel, Authorized
Signatory.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.